Showing results (21-30 of 41) with videos related to
Sort By:
Pageof 5
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 24, 2024
Folylpolyglutamate synthetase inactivation in relapsed ALL induces a druggable folate metabolic vulnerabilityHui Li, Yao Chen, Ming Ding, et al.Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Clonal Evolution of Pediatric Acute Myeloid Leukemia and Its Contribution to Disease RelapseMasayuki Umeda, Pandurang Kolekar, Anna Lw Huskey, et al.Molecular Cancer Research : MCR|January 18, 2019
The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin TreatmentSamuel W Brady, Xiaotu Ma, Armita Bahrami, et al.Blood|April 6, 2026
The ASH HematOmics Program supports integrative analysis of genomic and clinical data in hematologic diseasesCongyu Lu, Gavriel Y Matt, Robin Paul, et al.Blood Cancer Discovery|July 12, 2021
Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapySima Jeha, John Choi, Kathryn G Roberts, et al.Nature Communications|October 15, 2020
Pan-neuroblastoma analysis reveals age- and signature-associated driver alterationsSamuel W Brady, Yanling Liu, Xiaotu Ma, et al.Science Advances|April 29, 2026
IRS4 is a PI3K-activating cancer dependency up-regulated through DNA rearrangements or epigenetic mechanisms in multiple solid tumorsKhadija Banu, Mohammad Aslam Khan, Sihan Li, et al.Nature Cancer|February 5, 2022
Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapseFan Yang, Samuel W Brady, Chao Tang, et al.Leukemia|May 13, 2025
Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemiaRuth W Wang'ondu, Emily Ashcraft, Ti-Cheng Chang, et al.Nature Communications|January 29, 2025
Molecular and pharmacological heterogeneity of ETV6::RUNX1 acute lymphoblastic leukemiaZhenhua Li, Huanbin Zhao, Wenjian Yang, et al.Pageof 5